The article recommends two healthcare stocks for February 2026: CVS Health and Vertex Pharmaceuticals. CVS Health is positioned for long-term profitable growth after a strong 2025 rebound, with plans to streamline its Medicare Advantage and Obamacare businesses. Vertex Pharmaceuticals is expected to see strong commercial progress from newer drug launches (Casgevy and Journavx) and important clinical developments in 2026, diversifying beyond its core cystic fibrosis franchise.

While Centessa Pharmaceuticals shows promise with its ORX750 narcolepsy candidate, the article argues that Vertex Pharmaceuticals is a superior investment choice. Vertex has an established profitable business in cystic fibrosis, recent successful launches like Journavx and Casgevy, and a strong late-stage pipeline including zimislecel for Type 1 diabetes. Centessa, as a pre-revenue biotech, carries significantly higher risk despite its promising pipeline.

Vertex Pharmaceuticals is highlighted as a leading biotech investment opportunity, dominating the cystic fibrosis treatment market with drugs treating 90% of CF patients. The company is expanding into new growth areas with gene-editing treatment Casgevy for blood disorders and Journavx for pain management, with expectations of $13.1 billion in total revenue this year and at least $500 million from non-CF products.

The article examines whether Vertex Pharmaceuticals can achieve the 26% annual growth needed to turn $100,000 into $1 million by 2036. While Vertex has delivered an impressive 18.2% CAGR over the past decade, the article concludes this goal is unlikely. The company's cystic fibrosis franchise, though still a growth driver, faces limitations due to its larger size and smaller addressable patient population. Pipeline candidates show promise but would require near-flawless execution and sustained market leadership. Despite missing this lofty target, the article remains bullish on Vertex as a long-term hold due to its diversified product lineup and consistent revenue generation.

CRISPR Therapeutics stock rose over 12% following Q4 2025 earnings despite posting larger-than-expected net losses and minimal revenue ($0.86M) due to its revenue-sharing partnership with Vertex Pharmaceuticals on CASGEVY. The gene-editing company is in early stages with its flagship sickle cell/beta thalassemia therapy generating $54M in sales, while its pipeline candidate CTX611 for blood clot prevention shows promise. With $1.9B in cash providing 3-4 years of runway, analysts maintain a Hold consensus, though the stock trades near its 200-day moving average with downside risks.

CRISPR Therapeutics is highlighted as a promising biotech investment for 2026. The company's CRISPR-based gene-editing treatment Casgevy received FDA approval for blood disorders and has multi-billion-dollar potential. Multiple clinical trial updates and new trial launches are expected throughout 2026, which could serve as catalysts for stock growth.

Wall Street rebounded Friday after softer-than-expected inflation data reinforced expectations for interest-rate cuts. Annual inflation slowed to 2.4% in January, the lowest since May 2025, while core inflation eased to 2.5%. Small caps led gains with the Russell 2000 climbing 1.8%. Commodities surged with gold up 2%, silver up 4%, and Bitcoin rallying 4.6%. Strong earnings from tech and other sectors drove individual stock gains, with Rivian jumping 27% and Coinbase surging 17%.

CRISPR Therapeutics reported strong Q4 2025 results with Casgevy gene therapy generating $116 million in annual revenue and 147 patient initiations, nearly tripling from 2024. The company is advancing its pipeline with in vivo liver editing programs and RNA-based candidates. Shares surged 8.81% on the positive clinical progress and expanding market access.

Vertex Pharmaceuticals is highlighted as a biotech success story with strong leadership in cystic fibrosis treatment and successful expansion into other areas like gene editing and pain management. The author recommends buying and holding the stock long-term, citing Vertex's secured IP leadership through the late 2030s, billion-dollar CF earnings, and continued innovation including new drug candidates like Alyftrek that outperform existing blockbusters.

Vertex Pharmaceuticals is set to report earnings on Feb. 12 after underperforming the market with less than 2% gains over the past year. While Q3 revenue grew 11% to $3.08B, EPS rose only 4.7% due to increased R&D expenses. The company's newer therapies, including Alyftrek and Journavx, have disappointed with below-expected sales. Trading at a high valuation of 33x earnings, Vertex faces a high bar for its earnings report, though long-term prospects remain promising if it can expand its cystic fibrosis franchise.

The global targeted cancer therapy market is projected to grow from USD 90.89 billion in 2025 to USD 175.48 billion by 2035 at a CAGR of 6.80%. Growth is driven by antibody-drug conjugates (ADCs), KRAS inhibitors, bispecific antibodies, and regulatory productivity. Monoclonal antibodies capture 43% revenue share, lung cancer represents 32% of the market, and hospitals account for 58% of end-user share. North America dominates with 39% market share.

The global autologous cell therapy market, valued at $10.12 billion in 2024, is projected to grow to $44.55 billion by 2033 at a CAGR of 17.90%. Growth is driven by rising demand for personalized, patient-derived treatments for chronic diseases including cancer, cardiovascular disorders, and neurodegenerative conditions. North America leads the market with over 44% share, supported by a robust clinical trial ecosystem and regulatory frameworks like the FDA's RMAT designation.